- Home
- VERV vs PRLB Comparison
VERV vs PRLB Comparison
Compare VERV & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- PRLB
- Stock Information
- Founded
- VERV 2018
- PRLB 1999
- Country
- VERV United States
- PRLB United States
- Employees
- VERV N/A
- PRLB N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- PRLB Metal Fabrications
- Sector
- VERV Health Care
- PRLB Industrials
- Exchange
- VERV Nasdaq
- PRLB Nasdaq
- Market Cap
- VERV 1.0B
- PRLB 928.0M
- IPO Year
- VERV 2021
- PRLB 2012
- Fundamental
- Price
- VERV $11.06
- PRLB $40.13
- Analyst Decision
- VERV Buy
- PRLB Hold
- Analyst Count
- VERV 11
- PRLB 3
- Target Price
- VERV $14.57
- PRLB $43.00
- AVG Volume (30 Days)
- VERV 7.6M
- PRLB 169.2K
- Earning Date
- VERV 08-07-2025
- PRLB 08-01-2025
- Dividend Yield
- VERV N/A
- PRLB N/A
- EPS Growth
- VERV N/A
- PRLB N/A
- EPS
- VERV N/A
- PRLB 0.60
- Revenue
- VERV $59,613,000.00
- PRLB $499,205,000.00
- Revenue This Year
- VERV $47.32
- PRLB $4.18
- Revenue Next Year
- VERV N/A
- PRLB $4.61
- P/E Ratio
- VERV N/A
- PRLB $66.50
- Revenue Growth
- VERV 271.44
- PRLB N/A
- 52 Week Low
- VERV $2.87
- PRLB $25.76
- 52 Week High
- VERV $11.41
- PRLB $46.73
- Technical
- Relative Strength Index (RSI)
- VERV 78.23
- PRLB 53.85
- Support Level
- VERV $11.16
- PRLB $40.28
- Resistance Level
- VERV $11.30
- PRLB $41.63
- Average True Range (ATR)
- VERV 0.12
- PRLB 0.86
- MACD
- VERV -0.18
- PRLB 0.05
- Stochastic Oscillator
- VERV 12.50
- PRLB 60.03
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
About PRLB Proto Labs Inc. Common stock
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.